Evogene Ltd. (EVGN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Evogene Ltd. (EVGN:NASDAQ), powered by AI.

Current Price
$0.58
P/E Ratio
-0.5
Market Cap
5M
Sector
Healthcare
What is the Evogene Ltd. stock price forecast?

Evogene Ltd. is currently trading at $0.58. View real-time AI analysis on Alpha Lenz.

What is Evogene Ltd. insider trading activity?

View the latest insider trading data for Evogene Ltd. on Alpha Lenz.

What is Evogene Ltd.'s P/E ratio?

Evogene Ltd.'s P/E ratio is -0.5.

Evogene Ltd.

NASDAQ · EVGN
$0.58-0.01(-1.03%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Evogene Ltd.'s future dividend policy...
Alpha Chat Insight

Evogene Ltd. trades at a P/E of -0.5 (undervalued) with strong ROE of 1107.0%. 3Y revenue CAGR of 32.0% highlights clear growth momentum.

Ask for details

Company Overview

Evogene Ltd. is a biotechnology company that focuses on developing innovative solutions across various life science-based industries, including agriculture, pharmaceuticals, and industrial applications. By leveraging its unique computational predictive biology platform, Evogene aims to evolve new products through enhanced efficiency and precision. The platform integrates extensive databases, advanced algorithms, and big data analytics to identify and optimize traits that increase yield, resistance, and sustainability in crops or address critical health and industrial challenges. As a key player in sectors such as agrochemicals, seed development, and biotechnology, Evogene has established collaborations with leading companies to commercially scale its proprietary discoveries. The company is headquartered in Rehovot, Israel, contributing significantly to advancements in biotechnology that enhance productivity and sustainability, reflecting its growing importance in the global market for biologically driven solutions.

CEOMr. Ofer Haviv CPA
SectorHealthcare
IndustryBiotechnology
Employees117

Company Statistics

FY 2025

Profile

$4.60MMarket Cap
$3.85MRevenue
0.00Shares Out
117Employees

Margins

-6.25%Gross
-364.83%EBITDA
-364.24%Operating
-350.32%Pre-Tax
-203.14%Net

Valuation

-0.54P/E
-56.07P/B
1.19EV/Sales
-0.42EV/EBITDA
-0.34P/FCF

Growth (CAGR)

32.01%Rev 3Yr
29.94%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-26.13%ROA
1106.98%ROE
-44.54%ROIC

Financial Health

$12.96MCash & Cash Equivalents
$-4.88MNet Debt
67.40%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Evogene Ltd. (ticker: EVGN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 117 employees. Market cap is $5M.

The current price is $0.584 with a P/E ratio of -0.54x and P/B of -56.07x.

ROE is 1106.98% and operating margin is -364.24%. Annual revenue is $4M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Evogene Ltd. (EVGN) Stock Forecast 2026 $0.58 — Price, Financials & Analyst Targets | Alpha Lenz